Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial

Keyphrases

• Randomized Placebo-controlled Trial 100%
• Myocardial Injury 100%
• Dabigatran 100%
• Noncardiac Surgery 100%
• Placebo 63%
• Major Vascular Injury 36%
• Twice Daily 27%
• Hazard Ratio 18%
• Efficacy Outcomes 18%
• Primary Safety 18%
• Omeprazole 18%
• Cardiovascular Risk 9%
• Cardiovascular Mortality 9%
• Major Bleeding 9%
• Anticoagulant Therapy 9%
• Safety Outcomes 9%
• Major Organs 9%
• Once-daily 9%
• Proton Pump Inhibitors 9%
• Bleeding 9%
• Recurrent Venous Thromboembolism 9%
• Venous Thromboembolism 9%
• Non-hemorrhagic 9%
• Poor Prognosis 9%
• Composite Outcome 9%
• Life-threatening 9%
• Vascular Complications 9%
• 2-factorial Design 9%
• Nonfatal Myocardial Infarction 9%
• Hemorrhagic Stroke 9%
• Amputation 9%
• Canadian Institutes of Health Research 9%
• Vascular Mortality 9%
• Block Randomization 9%
• Critical Organ 9%
• Patient Health Care 9%
• Treatment Allocation 9%
• Randomization System 9%
• Adjudicator 9%
• Research Personnel 9%
• Intention-to-treat Principle 9%
• Data Collector 9%
• Peripheral Arterial Thrombosis 9%
• Upper Gastrointestinal Complications 9%

Medicine and Dentistry

• Placebo 100%
• Heart Muscle Injury 100%
• Dabigatran 100%
• Noncardiac Surgery 100%
• Hazard Ratio 18%
• Venous Thromboembolism 18%
• Omeprazole 18%
• Intention-to-Treat Analysis 9%
• Health Care Provider 9%
• Major Bleeding 9%
• Anticoagulant Therapy 9%
• Cardiovascular System 9%
• Bleeding 9%
• Myocardial Infarction 9%
• Proton-Pump Inhibitor 9%
• Cerebral Hemorrhage 9%
• Artery Thrombosis 9%
• Amputation 9%
• Gastrointestinal Complication 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Dabigatran 100%
• Heart Muscle Injury 100%
• Bleeding 18%
• Venous Thromboembolism 18%
• Omeprazole 18%
• Heart Infarction 9%
• Anticoagulation Therapy 9%
• Brain Hemorrhage 9%
• Artery Thrombosis 9%
• Proton Pump Inhibitor 9%